Renu Kondragunta
Associate Partner, EVERSANA MANAGEMENT CONSULTING
Expertise:
Renu Kondragunta is an Associate Partner at EVERSANA Management Consulting who brings her background in quantitative analysis and commercialization strategy to serve clients in the life sciences industry. At EVERSANA, she has worked on a variety of projects, including new product launch, long-term brand strategy, and customer engagement strategy. She has experience with a wide range of therapeutic areas, with particular emphasis on hematology, rare disease, and bone health.
Prior to joining EVERSANA Management Consulting, Renu worked at Stryker Orthopaedics in the clinical operations department where she developed optimized workflows and conducted quantitative analyses on clinical studies. During her graduate and undergraduate programs, Renu was involved with several medical device development and commercialization projects across a variety of therapeutic areas, including diabetes, orthopedics, and infectious diseases.
Renu earned her bachelor of science degree in biomedical engineering with a second major in applied mathematics and statistics from Johns Hopkins University and her master of science degree in bioengineering from Stanford University.
Articles by Renu Kondragunta
3 Questions You Need to Answer Before Partnering With Integrated Delivery Networks
Are you a pharmaceutical manufacturer looking to navigate the complex world of Integrated Delivery Networks (IDNs)? These powerful entities, which manage multiple healthcare facilities, are key players in delivering high-quality, cost-effective, and patient-centered care. But how can you effectively engage with them to drive sales and support patient outcomes? In our latest white paper, “3 Questions You Need to Answer Before Partnering With Integrated Delivery Networks,” we dive deep into the critical considerations for building successful partnerships with IDNs. You’ll discover how IDNs operate, their business objectives, and their profound impact on the healthcare landscape. Learn how these networks leverage their scale to negotiate lower drug acquisition costs and focus […]